Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial
In the multicenter VOLTAGE-2 trial, investigators will compare results of the company's tests with standard-of-care measures of drug response.
Personalis to Test MRD Assay in Triple-Negative Breast Cancer Trial With ABRCC, Criterium
The company has partnered with the Academic Breast Cancer Consortium and Criterium to assess its test in a prospective trial with five years of follow-up.
Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology for up to $450M
The lab testing giant will add Haystack's minimal residual disease technology to its suite of genomic and other clinical services.
Foresight Diagnostics Closes $58.8M Series B Round
The Aurora, Colorado-based company plans to accelerate the clinical development and commercialization of its PhasED-seq MRD testing platform.
Quest Adds to Cancer Portfolio With $450M Buy of Haystack Oncology; Q1 Revenues Down 11 Percent
Premium
The firm said the acquisition let it move into the "fast growing" MRD space and round out its offerings in cancer screening, pathology, and sequencing.